<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03416127</url>
  </required_header>
  <id_info>
    <org_study_id>PROPOLIS-METFORMIN-DM2</org_study_id>
    <nct_id>NCT03416127</nct_id>
  </id_info>
  <brief_title>Effect of Propolis or Metformin Administration on Glycemic Control in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effect of Propolis or Metformin Administration on Glycemic Control in Patients With Type 2 Diabetes Mellitus Without Pharmacological Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glycemic control is naturally the principal topic of diabetes and complications that can be&#xD;
      developed as a consequence of loss of sensitivity to perceive insulin signals by the cell.&#xD;
      The glycemic control goals established by the ADA are: glycosylated hemoglobin (A1C) &lt;7.0%,&#xD;
      fasting plasma glucose 80-130 mg/dL and casual plasma glycemia &lt;180 mg/dL. The first-line&#xD;
      treatment in patients of recent diagnosis is metformin, however, studies have shown that&#xD;
      propolis, a resinous balsamic material collected by the Apis mellifera bee, from sprouts,&#xD;
      exudates of trees and other parts of the plants, represents a very important and promising&#xD;
      natural alternative in medicine, which can be considered as an antidiabetic agent.&#xD;
&#xD;
      The aim of this study is to evaluate the effect of propolis or metformin administration on&#xD;
      glycemic control in patients with type 2 Diabetes Mellitus without pharmacological treatment.&#xD;
&#xD;
      The investigators hypothesis is that propolis or metformin administration, modify the&#xD;
      glycemic control in patients with type 2 Diabetes Mellitus without pharmacological treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, randomized clinical trial of three pharmacological groups in 36 patients with&#xD;
      a diagnosis of diabetes mellitus type 2 in accordance with the American Diabetes Association&#xD;
      (ADA) without treatment.&#xD;
&#xD;
      They will be assigned randomly three groups of 12 patients, each one will receive propolis&#xD;
      300 mg, metformin 850 mg and placebo, two times per day before having break-fast and before&#xD;
      having dinner during 12 weeks.&#xD;
&#xD;
      The Area Under the Curve of glucose and insulin will be calculated, total insulin secretion&#xD;
      (Insulinogenic index), first-phase of insulin secretion (Stumvoll index) and insulin&#xD;
      sensitivity (Matsuda index).&#xD;
&#xD;
      This protocol is already approved by the local ethics committee and written informed consent&#xD;
      it's going to be obtained from all volunteers.&#xD;
&#xD;
      Statistical analysis will be presented through measures of central tendency and dispersion,&#xD;
      average and deviation standard for quantitative variables; frequencies and percentages for&#xD;
      variable qualitative. Qualitative variables will be analyzed by X2, will be used for&#xD;
      differences inter-group Mann-Whitney U Test and Wilcoxon Test for the within-groups&#xD;
      differences. It will be considered statistical significance p ≤0.05.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Actual">December 20, 2019</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting Serum Glucose</measure>
    <time_frame>Week 12</time_frame>
    <description>The fasting glucose levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2 Hours After Oral Glucose Tolerance Test in Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>2-h serum glucose levels were evaluated at week 12 after a oral glucose tolerance test with enzymatic/colorimetric techniques and the entered values reflect the insulin sensitivity at week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycosylated Hemoglobin (A1C)</measure>
    <time_frame>Week 12</time_frame>
    <description>Glycosylated hemoglobin was evaluated at week 12 by high pressure liquid chromatography (HPLC) and the entered values reflect the glycosylated hemoglobin at week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Insulin Secretion</measure>
    <time_frame>Week 12</time_frame>
    <description>Total insulin secretion was calculated at week 12 with insulinogenic index and the entered values reflect the total insulin secretion at week 12.&#xD;
The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>Week 12</time_frame>
    <description>Insulin sensitivity was calculated at week 12 with Matsuda index and the entered values reflect the insulin sensitivity at week 12.&#xD;
Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Phase of Insulin Secretion</measure>
    <time_frame>Week 12</time_frame>
    <description>The first phase of insulin secretion was calculated at week 12 with Stumvoll index and the entered values reflect the frst phase of insulin secretion at week 12.&#xD;
Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC Glucose</measure>
    <time_frame>Week 12</time_frame>
    <description>Area under the curve (AUC) of glucose was calculated with the polygonal formula.&#xD;
The area under the curve (AUC) of glucose, (0.5 * glucose (G) 0´ + (G 30´+G 60´ + G 90´) + 0.5 * G 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC Insulin</measure>
    <time_frame>Week 12</time_frame>
    <description>Area under the curve (AUC) of insulin was calculated with the polygonal formula.&#xD;
The area under the curve (AUC) of insulin, (0.5 * Insulin (I) 0´ + (I 30´+I 60´ + I 90´) + 0.5 * I 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperinsulinemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose 30 Min After Oral Glucose Tolerance Test at 12 Week</measure>
    <time_frame>Week 12</time_frame>
    <description>The glucose levels 30' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 30' at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose 60 Min After Oral Glucose Tolerance Test at 12 Week</measure>
    <time_frame>Week 12</time_frame>
    <description>The glucose levels 60' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 60' at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose 90 Min After Oral Glucose Tolerance Test at 12 Week</measure>
    <time_frame>Week 12</time_frame>
    <description>The glucose levels 90' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 90' at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>Week 12</time_frame>
    <description>Waist circumference was evaluated at week 12 with a flexible tape</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>Week 12</time_frame>
    <description>The body weight was measured at week 12 with a bioimpedance balance and the entered values reflect the body weight at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>Week 12</time_frame>
    <description>Body Mas Index was calculated at week 12 with the Quetelet index formula and the entered values reflect the body mass index at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Fat Mass</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of fat mass was evaluated through bioimpedance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>Week 12</time_frame>
    <description>Total cholesterol levels were evaluated at week 12 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>Week 12</time_frame>
    <description>Triglycerides levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein Cholesterol (c-HDL)</measure>
    <time_frame>Week 12</time_frame>
    <description>c-HDL levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoproteins Cholesterol (c-LDL)</measure>
    <time_frame>Week 12</time_frame>
    <description>c-LDL levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-LDL level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very Low Density Lipoprotein (c-VLDL)</measure>
    <time_frame>Week 12</time_frame>
    <description>Very low density lipoprotein (c-VLDL) was analyzed with the cholesterol oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>Week 12</time_frame>
    <description>Creatinine levels were evaluated at week 12 with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric Acid</measure>
    <time_frame>Week 12</time_frame>
    <description>Uric acid levels were evaluated at week 12 with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>Week 12</time_frame>
    <description>The systolic blood pressure was evaluated at week 12 with a digital sphygmomanometer and the entered values reflect the systolic blood pressure at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>Week 12</time_frame>
    <description>The diastolic blood pressure was evaluated at week 12 with a digital sphygmomanometer and the entered values reflect the diastolic blood pressure at week 12.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Propolis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propolis</intervention_name>
    <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
    <arm_group_label>Propolis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Metformin hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Calcined magnesium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients both sexes&#xD;
&#xD;
          -  Age between 30 and 60 years&#xD;
&#xD;
          -  Diabetes mellitus type 2 of recent diagnosis without pharmacological treatment, with&#xD;
             one of the following criteria (fasting blood glucose levels &gt;126 mg/dl; postprandial&#xD;
             blood glucose levels after an oral glucose tolerance test with 75 of oral glucose &gt;200&#xD;
             mg/dl; or glycosylated hemoglobin between &gt;6.5%)&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with confirmed or suspected pregnancy&#xD;
&#xD;
          -  Women under lactation and/or puerperium&#xD;
&#xD;
          -  Previous treatment for glucose&#xD;
&#xD;
          -  Fasting glucose ≥250 mg/dL&#xD;
&#xD;
          -  Body Mass Index ≥34.9 kg/m2&#xD;
&#xD;
          -  Known uncontrolled renal, hepatic, heart or thyroid diseased&#xD;
&#xD;
          -  Hypersensibility to ingredients of intervention&#xD;
&#xD;
          -  Known allergies to bee stings or their derived products&#xD;
&#xD;
          -  Triglycerides ≥500 mg/dL&#xD;
&#xD;
          -  Total cholesterol ≥240 mg/dL&#xD;
&#xD;
          -  Low density lipoprotein (c-LDL) ≥190 mg/dL&#xD;
&#xD;
          -  Blood Pressure ≥140/90 mmHg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MANUEL GONZALEZ, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intstituto de Terapeútica Experimental y Clínica.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intstituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <results_first_submitted>August 25, 2020</results_first_submitted>
  <results_first_submitted_qc>September 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2020</results_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Manuel González Ortiz</investigator_full_name>
    <investigator_title>Researcher Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus type 2</keyword>
  <keyword>Glycemic control</keyword>
  <keyword>Propolis</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Propolis</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT03416127/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT03416127/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Propolis</title>
          <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Metformin</title>
          <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Propolis</title>
          <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Metformin</title>
          <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="7"/>
                    <measurement group_id="B2" value="51" spread="4"/>
                    <measurement group_id="B3" value="50" spread="5"/>
                    <measurement group_id="B4" value="49" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting serum glucose</title>
          <description>Fasting serum glucose was analyzed with the glucose oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" spread="1.4"/>
                    <measurement group_id="B2" value="8.0" spread="1.6"/>
                    <measurement group_id="B3" value="7.7" spread="1.2"/>
                    <measurement group_id="B4" value="7.7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2 hours after OGTT</title>
          <description>2-h serum glucose was analyzed with the glucose oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.6" spread="2.1"/>
                    <measurement group_id="B2" value="15.8" spread="2.8"/>
                    <measurement group_id="B3" value="13.2" spread="1.9"/>
                    <measurement group_id="B4" value="14.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin (A1C)</title>
          <description>Glycosylated Hemoglobin (A1C) was evaluated with liquid chromatography method.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.6" spread="0.8"/>
                    <measurement group_id="B2" value="6.8" spread="0.9"/>
                    <measurement group_id="B3" value="6.8" spread="0.9"/>
                    <measurement group_id="B4" value="6.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total insulin secretion</title>
          <description>The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.5" spread="0.1"/>
                    <measurement group_id="B2" value="0.4" spread="0.2"/>
                    <measurement group_id="B3" value="0.5" spread="0.1"/>
                    <measurement group_id="B4" value="0.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin sensitivity</title>
          <description>Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" spread="0.4"/>
                    <measurement group_id="B2" value="1.1" spread="0.3"/>
                    <measurement group_id="B3" value="0.8" spread="0.3"/>
                    <measurement group_id="B4" value="1.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>First phase of insulin secretion</title>
          <description>Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2092" spread="653"/>
                    <measurement group_id="B2" value="1608" spread="736"/>
                    <measurement group_id="B3" value="2221" spread="566"/>
                    <measurement group_id="B4" value="1984" spread="686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AUC glucose</title>
          <description>Area under the curve (AUC) of glucose and insulin was calculated with the polygonal formula.</description>
          <units>mmol/L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17380" spread="2464"/>
                    <measurement group_id="B2" value="18727" spread="3128"/>
                    <measurement group_id="B3" value="16749" spread="1627"/>
                    <measurement group_id="B4" value="17619" spread="2553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AUC insulin</title>
          <description>Area under the curve (AUC) of glucose and insulin was calculated with the polygonal formula.</description>
          <units>pmol/L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8757" spread="1527"/>
                    <measurement group_id="B2" value="7554" spread="1501"/>
                    <measurement group_id="B3" value="8978" spread="842"/>
                    <measurement group_id="B4" value="8439" spread="1439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose 30 min after oral glucose tolerance test</title>
          <description>Glucose 30' was analyzed with the glucose oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.4" spread="2.3"/>
                    <measurement group_id="B2" value="13.7" spread="3.8"/>
                    <measurement group_id="B3" value="12.0" spread="1.3"/>
                    <measurement group_id="B4" value="12.7" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose 60 min after oral glucose tolerance test</title>
          <description>Glucose 60' was analyzed with the glucose oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.2" spread="3.0"/>
                    <measurement group_id="B2" value="17.2" spread="2.9"/>
                    <measurement group_id="B3" value="14.7" spread="1.9"/>
                    <measurement group_id="B4" value="15.6" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose 90 min after oral glucose tolerance test</title>
          <description>Glucose 90' was analyzed with the glucose oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.7" spread="2.0"/>
                    <measurement group_id="B2" value="17.5" spread="2.4"/>
                    <measurement group_id="B3" value="14.3" spread="2.8"/>
                    <measurement group_id="B4" value="15.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist circumference</title>
          <description>Waist circumference was measured with a flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101.2" spread="9.6"/>
                    <measurement group_id="B2" value="103.4" spread="11.7"/>
                    <measurement group_id="B3" value="103.2" spread="10.2"/>
                    <measurement group_id="B4" value="102.6" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <description>Body weight was evaluated through a bioimpedance digital scale and results are reported in kg with a decimal.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.4" spread="11.5"/>
                    <measurement group_id="B2" value="80.7" spread="14.4"/>
                    <measurement group_id="B3" value="78.6" spread="13.1"/>
                    <measurement group_id="B4" value="78.6" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <description>Body mass index was calculated as weight (kg) divided by height (m2).</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.0" spread="4.4"/>
                    <measurement group_id="B2" value="29.1" spread="3.7"/>
                    <measurement group_id="B3" value="30.2" spread="3.13"/>
                    <measurement group_id="B4" value="29.5" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of fat mass</title>
          <description>Percentage of fat mass was evaluated through bioimpedance.</description>
          <units>% fat mass</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.8" spread="9.7"/>
                    <measurement group_id="B2" value="30.7" spread="6.8"/>
                    <measurement group_id="B3" value="33.8" spread="8.3"/>
                    <measurement group_id="B4" value="32.4" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol</title>
          <description>Total cholesterol was analyzed with the cholesterol oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.0" spread="0.8"/>
                    <measurement group_id="B2" value="4.7" spread="1.1"/>
                    <measurement group_id="B3" value="4.7" spread="0.5"/>
                    <measurement group_id="B4" value="4.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <description>Triglycerides were analyzed with the triglycerides oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" spread="1.1"/>
                    <measurement group_id="B2" value="1.7" spread="0.6"/>
                    <measurement group_id="B3" value="2.0" spread="1.0"/>
                    <measurement group_id="B4" value="2.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Density Lipoprotein cholesterol (c-HDL)</title>
          <description>High-density lipoprotein cholesterol (c-HDL) was analyzed with the cholesterol oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" spread="0.3"/>
                    <measurement group_id="B2" value="0.9" spread="0.3"/>
                    <measurement group_id="B3" value="0.9" spread="0.2"/>
                    <measurement group_id="B4" value="0.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-Density Lipoproteins-cholesterol (c-LDL)</title>
          <description>Low-density lipoprotein-cholesterol (c-LDL) was calculated with the Friedewald formula as follows: LDL-c (mmol/L)= TC (mmol/L) - HDL-c (mmol/L) - [TG(mmol/L)/2.2]</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.0" spread="0.8"/>
                    <measurement group_id="B2" value="3.0" spread="0.8"/>
                    <measurement group_id="B3" value="2.9" spread="0.5"/>
                    <measurement group_id="B4" value="3.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Very low density lipoprotein (VLDL)</title>
          <description>Very low density cholesterol (c-VLDL) was analyzed with the cholesterol oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" spread="0.5"/>
                    <measurement group_id="B2" value="0.8" spread="0.3"/>
                    <measurement group_id="B3" value="0.9" spread="0.5"/>
                    <measurement group_id="B4" value="0.9" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine</title>
          <description>Creatinine was analyzed with the alkaline picrate technique by enzymatic colorimetric methods on an automatic analyzer.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.5" spread="31.8"/>
                    <measurement group_id="B2" value="65.4" spread="21.2"/>
                    <measurement group_id="B3" value="69.8" spread="27.4"/>
                    <measurement group_id="B4" value="70.7" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Uric acid</title>
          <description>Uric acid was analyzed with the uric acid oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="356.9" spread="71.4"/>
                    <measurement group_id="B2" value="315.2" spread="65.4"/>
                    <measurement group_id="B3" value="309.2" spread="89.2"/>
                    <measurement group_id="B4" value="327.1" spread="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <description>Blood pressure was evaluated with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of systolic blood pressure (SBP) and diastolic (DBP).</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116.9" spread="8.7"/>
                    <measurement group_id="B2" value="118.4" spread="10.6"/>
                    <measurement group_id="B3" value="115.7" spread="7.2"/>
                    <measurement group_id="B4" value="117.0" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <description>Blood pressure was evaluated with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of systolic blood pressure (SBP) and diastolic (DBP).</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.5" spread="7.8"/>
                    <measurement group_id="B2" value="76.2" spread="7.0"/>
                    <measurement group_id="B3" value="73.4" spread="6.7"/>
                    <measurement group_id="B4" value="75.4" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fasting Serum Glucose</title>
        <description>The fasting glucose levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Serum Glucose</title>
          <description>The fasting glucose levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 12</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="0.9"/>
                    <measurement group_id="O2" value="7.3" spread="1.1"/>
                    <measurement group_id="O3" value="8.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>2 Hours After Oral Glucose Tolerance Test in Week 12</title>
        <description>2-h serum glucose levels were evaluated at week 12 after a oral glucose tolerance test with enzymatic/colorimetric techniques and the entered values reflect the insulin sensitivity at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>2 Hours After Oral Glucose Tolerance Test in Week 12</title>
          <description>2-h serum glucose levels were evaluated at week 12 after a oral glucose tolerance test with enzymatic/colorimetric techniques and the entered values reflect the insulin sensitivity at week 12</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="1.9"/>
                    <measurement group_id="O2" value="13.7" spread="2.7"/>
                    <measurement group_id="O3" value="13.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.963</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glycosylated Hemoglobin (A1C)</title>
        <description>Glycosylated hemoglobin was evaluated at week 12 by high pressure liquid chromatography (HPLC) and the entered values reflect the glycosylated hemoglobin at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Hemoglobin (A1C)</title>
          <description>Glycosylated hemoglobin was evaluated at week 12 by high pressure liquid chromatography (HPLC) and the entered values reflect the glycosylated hemoglobin at week 12</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>% of A1C</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="0.9"/>
                    <measurement group_id="O2" value="6.6" spread="0.8"/>
                    <measurement group_id="O3" value="7.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.236</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Insulin Secretion</title>
        <description>Total insulin secretion was calculated at week 12 with insulinogenic index and the entered values reflect the total insulin secretion at week 12.&#xD;
The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.&#xD;
Period Title: Overall Study</description>
          </group>
        </group_list>
        <measure>
          <title>Total Insulin Secretion</title>
          <description>Total insulin secretion was calculated at week 12 with insulinogenic index and the entered values reflect the total insulin secretion at week 12.&#xD;
The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.2"/>
                    <measurement group_id="O2" value="0.3" spread="0.2"/>
                    <measurement group_id="O3" value="0.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity</title>
        <description>Insulin sensitivity was calculated at week 12 with Matsuda index and the entered values reflect the insulin sensitivity at week 12.&#xD;
Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.&#xD;
Period Title: Overall Study</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>Insulin sensitivity was calculated at week 12 with Matsuda index and the entered values reflect the insulin sensitivity at week 12.&#xD;
Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.6"/>
                    <measurement group_id="O2" value="1.8" spread="1.0"/>
                    <measurement group_id="O3" value="1.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>First Phase of Insulin Secretion</title>
        <description>The first phase of insulin secretion was calculated at week 12 with Stumvoll index and the entered values reflect the frst phase of insulin secretion at week 12.&#xD;
Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>First Phase of Insulin Secretion</title>
          <description>The first phase of insulin secretion was calculated at week 12 with Stumvoll index and the entered values reflect the frst phase of insulin secretion at week 12.&#xD;
Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1346" spread="784"/>
                    <measurement group_id="O2" value="1022" spread="709"/>
                    <measurement group_id="O3" value="1621" spread="830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.162</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC Glucose</title>
        <description>Area under the curve (AUC) of glucose was calculated with the polygonal formula.&#xD;
The area under the curve (AUC) of glucose, (0.5 * glucose (G) 0´ + (G 30´+G 60´ + G 90´) + 0.5 * G 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperglycemia.</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC Glucose</title>
          <description>Area under the curve (AUC) of glucose was calculated with the polygonal formula.&#xD;
The area under the curve (AUC) of glucose, (0.5 * glucose (G) 0´ + (G 30´+G 60´ + G 90´) + 0.5 * G 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperglycemia.</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>mmol/L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16600" spread="2274"/>
                    <measurement group_id="O2" value="15967" spread="5411"/>
                    <measurement group_id="O3" value="15509" spread="5345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.686</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC Insulin</title>
        <description>Area under the curve (AUC) of insulin was calculated with the polygonal formula.&#xD;
The area under the curve (AUC) of insulin, (0.5 * Insulin (I) 0´ + (I 30´+I 60´ + I 90´) + 0.5 * I 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperinsulinemia.</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC Insulin</title>
          <description>Area under the curve (AUC) of insulin was calculated with the polygonal formula.&#xD;
The area under the curve (AUC) of insulin, (0.5 * Insulin (I) 0´ + (I 30´+I 60´ + I 90´) + 0.5 * I 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperinsulinemia.</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>pmol/L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7354" spread="2230"/>
                    <measurement group_id="O2" value="4217" spread="2859"/>
                    <measurement group_id="O3" value="7835" spread="2736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose 30 Min After Oral Glucose Tolerance Test at 12 Week</title>
        <description>The glucose levels 30' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 30' at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose 30 Min After Oral Glucose Tolerance Test at 12 Week</title>
          <description>The glucose levels 30' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 30' at week 12</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="2.0"/>
                    <measurement group_id="O2" value="12.5" spread="2.1"/>
                    <measurement group_id="O3" value="12.0" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.945</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose 60 Min After Oral Glucose Tolerance Test at 12 Week</title>
        <description>The glucose levels 60' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 60' at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose 60 Min After Oral Glucose Tolerance Test at 12 Week</title>
          <description>The glucose levels 60' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 60' at week 12</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="2.8"/>
                    <measurement group_id="O2" value="15.9" spread="2.5"/>
                    <measurement group_id="O3" value="14.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.332</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose 90 Min After Oral Glucose Tolerance Test at 12 Week</title>
        <description>The glucose levels 90' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 90' at week 12.</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose 90 Min After Oral Glucose Tolerance Test at 12 Week</title>
          <description>The glucose levels 90' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 90' at week 12.</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="2.6"/>
                    <measurement group_id="O2" value="16.6" spread="2.1"/>
                    <measurement group_id="O3" value="14.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.075</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference</title>
        <description>Waist circumference was evaluated at week 12 with a flexible tape</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference</title>
          <description>Waist circumference was evaluated at week 12 with a flexible tape</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.7" spread="10.0"/>
                    <measurement group_id="O2" value="102.2" spread="11.9"/>
                    <measurement group_id="O3" value="101.5" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.903</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight</title>
        <description>The body weight was measured at week 12 with a bioimpedance balance and the entered values reflect the body weight at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight</title>
          <description>The body weight was measured at week 12 with a bioimpedance balance and the entered values reflect the body weight at week 12</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="11.3"/>
                    <measurement group_id="O2" value="81.0" spread="15.2"/>
                    <measurement group_id="O3" value="77.8" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.697</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index</title>
        <description>Body Mas Index was calculated at week 12 with the Quetelet index formula and the entered values reflect the body mass index at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index</title>
          <description>Body Mas Index was calculated at week 12 with the Quetelet index formula and the entered values reflect the body mass index at week 12</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" spread="4.3"/>
                    <measurement group_id="O2" value="29.2" spread="3.8"/>
                    <measurement group_id="O3" value="30.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.668</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Fat Mass</title>
        <description>Percentage of fat mass was evaluated through bioimpedance.</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Fat Mass</title>
          <description>Percentage of fat mass was evaluated through bioimpedance.</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>% of fat mass</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" spread="10.3"/>
                    <measurement group_id="O2" value="28.4" spread="6.8"/>
                    <measurement group_id="O3" value="33.6" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.308</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol</title>
        <description>Total cholesterol levels were evaluated at week 12 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol</title>
          <description>Total cholesterol levels were evaluated at week 12 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at week 12</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="0.7"/>
                    <measurement group_id="O2" value="4.6" spread="0.9"/>
                    <measurement group_id="O3" value="4.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.318</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides</title>
        <description>Triglycerides levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides</title>
          <description>Triglycerides levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at week 12</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.8"/>
                    <measurement group_id="O2" value="2.0" spread="1.0"/>
                    <measurement group_id="O3" value="1.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.880</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Density Lipoprotein Cholesterol (c-HDL)</title>
        <description>c-HDL levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>High Density Lipoprotein Cholesterol (c-HDL)</title>
          <description>c-HDL levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at week 12</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.3"/>
                    <measurement group_id="O2" value="0.9" spread="0.2"/>
                    <measurement group_id="O3" value="0.9" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.376</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Density Lipoproteins Cholesterol (c-LDL)</title>
        <description>c-LDL levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-LDL level at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Low Density Lipoproteins Cholesterol (c-LDL)</title>
          <description>c-LDL levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-LDL level at week 12</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.5"/>
                    <measurement group_id="O2" value="2.7" spread="0.5"/>
                    <measurement group_id="O3" value="3.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.210</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Very Low Density Lipoprotein (c-VLDL)</title>
        <description>Very low density lipoprotein (c-VLDL) was analyzed with the cholesterol oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Very Low Density Lipoprotein (c-VLDL)</title>
          <description>Very low density lipoprotein (c-VLDL) was analyzed with the cholesterol oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.4"/>
                    <measurement group_id="O2" value="0.9" spread="0.5"/>
                    <measurement group_id="O3" value="0.9" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.880</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine</title>
        <description>Creatinine levels were evaluated at week 12 with enzymatic/colorimetric techniques</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine</title>
          <description>Creatinine levels were evaluated at week 12 with enzymatic/colorimetric techniques</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.7" spread="10.6"/>
                    <measurement group_id="O2" value="74.2" spread="16.8"/>
                    <measurement group_id="O3" value="63.6" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.059</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uric Acid</title>
        <description>Uric acid levels were evaluated at week 12 with enzymatic/colorimetric techniques</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Uric Acid</title>
          <description>Uric acid levels were evaluated at week 12 with enzymatic/colorimetric techniques</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339.0" spread="77.3"/>
                    <measurement group_id="O2" value="327.1" spread="71.4"/>
                    <measurement group_id="O3" value="333.1" spread="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.978</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>The systolic blood pressure was evaluated at week 12 with a digital sphygmomanometer and the entered values reflect the systolic blood pressure at week 12.</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>The systolic blood pressure was evaluated at week 12 with a digital sphygmomanometer and the entered values reflect the systolic blood pressure at week 12.</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.6" spread="7.4"/>
                    <measurement group_id="O2" value="119.2" spread="11.4"/>
                    <measurement group_id="O3" value="112.8" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.122</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <description>The diastolic blood pressure was evaluated at week 12 with a digital sphygmomanometer and the entered values reflect the diastolic blood pressure at week 12.</description>
        <time_frame>Week 12</time_frame>
        <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Propolis</title>
            <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>The diastolic blood pressure was evaluated at week 12 with a digital sphygmomanometer and the entered values reflect the diastolic blood pressure at week 12.</description>
          <population>Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8" spread="7.4"/>
                    <measurement group_id="O2" value="74.4" spread="7.9"/>
                    <measurement group_id="O3" value="72.3" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.551</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study, an average of 12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Propolis</title>
          <description>Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Propolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Metformin</title>
          <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.&#xD;
Metformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo capsules, two times per day before break-fast and dinner during 12 weeks.&#xD;
Placebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Loose stools</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>DR. MANUEL GONZALEZ ORTIZ</name_or_title>
      <organization>INSTITUTO DE TERAPEUTICA EXPERIMENTAL Y CLINICA</organization>
      <phone>+52 3310585200 ext 34212</phone>
      <email>uiec@prodigy.net.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

